NCT02646072

Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients

The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: University of Malaya · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether there is a relationship between inflammatory cytokines in the aqueous of the eye and thickness of the macula after treatment of topical ketorolac for patients undergoing cataract surgery.

Detailed description

To compare aqueous levels of inflammatory cytokines in diabetic and non diabetic patients treated with preoperative topical ketorolac tromethamine 0.45%. To compare the macular thickness changes in diabetic and non diabetic patients treated with preoperative ketorolac tromethamine 0.45% and its correlation with the aqueous inflammatory cytokines.

Conditions

• Cystoid Macular Edema, Postoperative
• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Ketorolac tromethamine ophthalmic solution 0.45%	Indicated for the treatment of pain and inflammation following cataract surgery.

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-05-01
• Completion: 2015-06-01
• First posted: 2016-01-05
• Last updated: 2016-01-05

Locations

1 site across 1 country: Malaysia